CNC

Business Profile & Competitive Position

Centene Corp. (CNC) sits in the Healthcare sector under the Medical – Healthcare Plans industry. It describes itself as the nation’s largest managed-care company focused on underserved populations, offering Medicaid, Medicare Advantage, Prescription Drug Plans (PDP), Medicare Supplement products, and commercial Marketplace coverage, largely under local brands such as Health Net and Ambetter. As of December 31, 2025, total membership reached 27.6 million: 12.5 million Medicaid, 5.5 million Marketplace, and 8.1 million stand-alone PDP members. Full-year 2025 revenue was $194.8 billion, split 57% Medicaid, 21% commercial, 19% Medicare, and 3% other.

That membership base is the company’s clearest competitive asset. Centene is the largest Medicaid insurer, the largest Marketplace insurer, and the largest stand-alone PDP provider in the United States. Scale of that magnitude lowers per-member administrative costs and creates bargaining leverage with hospitals and pharmacy networks. At the same time, the numbers also show that scale has not recently translated into profitable returns: the net margin is -2.6% and return on equity is -24.0%. Those figures suggest the moat is one of enrollment density and government-contract positioning rather than strong current pricing power or margin quality. Ongoing transition items—such as the December 2025 definitive agreement to divest the remaining Magellan Health businesses—may be contributing to the weak headline profitability.

Financial Posture

Centene’s market capitalization is $30.5 billion, and it currently trades at a P/E ratio of -5.9. A negative P/E is not a traditional value signal; it simply reflects that the company has been reporting losses. The -2.6% net margin and -24.0% ROE confirm that mesmo at scale, capital is being eroded rather than compounded in the most recent accounting period. Investors are therefore weighing the current red ink against the possibility of normalized or cash-adjusted earnings power.

One mitigating factor is cash generation: operating cash flow in 2025 was $5.1 billion, materially higher than the reported net loss. Premium collection continues to convert to cash even while accounting margins are underwater. The stock’s beta is 1.11, meaning it has tended to move slightly more than the broad market. As of the latest snapshot, CNC trades at $61.8, with an RSI of 39.5 and a 50-day exponential moving average of $64.48. Price sits just below that medium-term average and RSI is approaching—but not yet in—oversold territory.

Strategic Priorities & Outlook

Centene’s most recent 10-K filing outlines a clear set of near-term operational priorities. The company plans to continue refining its Medicare footprint so that it overlaps more closely with Medicaid operations, while expanding Dual-Eligible Special Needs Plan (D-SNP) offerings aligned with CMS requirements taking effect through 2030. D-SNP expansion is framed as a long-term growth driver because it serves members eligible for both Medicaid and Medicare.

The filing also highlights policy advocacy and commercial pricing actions. Centene intends to advocate for legislation that preserves affordable Medicaid and Marketplace coverage, and for cost-effective, high-quality care for PDP members. On the commercial side, it plans to implement 2026 corrective Marketplace pricing actions in states covering 95% of Marketplace membership, while expanding Ambetter Health Solutions / ICHRA-compatible off-exchange coverage from 6 states to 13 states. These priorities link directly to the revenue mix: stabilizing Marketplace margins and growing D-SNP are the two levers most tied to the bottom line.

Macro & Geopolitical Exposure

As a healthcare plans company, Centene’s economics are heavily tied to regulation and public budgets. Medicaid is funded jointly by federal and state governments, so changes to federal matching rates, state budget stress, work-requirement rules, or eligibility redeterminations directly affect enrollment and margins. Medicare Advantage and PDP plans are governed by CMS rate announcements, star ratings, and rule changes; the 10-K explicitly cites CMS requirements rolling through 2030 as a factor in product design.

Beyond legislation and regulation, the sector is exposed to medical-cost inflation, prescription-drug pricing policy, utilization trends, and the level of Affordable Care Act Marketplace subsidies. Macroeconomic variables such as employment levels also matter, since Medicaid rolls typically expand in weaker labor markets and contract when unemployment is low. Climate and infrastructure events can drive claims and administrative costs higher, because health plans often provide member assistance, provider relief, and extended coverage during wildfires, sewage spills, and severe weather.

Recent Developments

The most recent headlines are a mix of investment commentary and operating-community updates. On September 25, 2026, Zacks published “Here’s Why Centene (CNC) is a Strong Value Stock,” and on September 24, 2026, Zacks included the company in “Best Growth Stocks to Buy for September 24th.” Both pieces are thematic strategy articles rather than company-specific news or analyst actions.

On September 22, 2026, Centene’s Health Net subsidiary announced it was providing special assistance to members and providers affected by statewide weather events and the Robin Lane sewage spill in Lake County. The same day, Health Net publicized a $3 million investment that helped Stockton seniors gain access to 76 affordable homes. These releases illustrate Centene’s local-brand, community-embedded model, and they highlight the social-determinants spending that can affect member utilization, brand perception, and state regulatory relationships.

Earnings Behavior & Post-Earnings Drift

Centene’s earnings record is statistically strong but not straightforward to trade. Over the last eight reported quarters, the company has beaten expectations 7 times for an 88% beat rate, and the average earnings surprise is 63.1%. Across those quarters, the average five-session drift after the report is 2.83%, classified as an “up” drift.

The last four reports show why the headline beat rate tells only part of the story. On July 28, 2026, Centene reported $2.51 EPS versus a $1.09 estimate, a 130.3% surprise, yet the stock fell 3.27% the next day and gained only 0.25% over the following five sessions. The prior quarter, April 28, 2026, delivered $3.37 versus $2.23 (51.1% surprise) and produced a strong 8.9% next-day gain and a 6.88% five-day drift. On February 6, 2026, EPS of -$1.19 beat the -$1.22007 estimate by 2.5%, the stock slipped 1.09% the next day, but then drifted 5.51% higher over five days. The October 29, 2025 quarter delivered the largest surprise in the set, $0.50 versus -$0.14475 (445.4%), but the stock sold off 6.21% the next day and drifted -1.34% over the following week.

In other words, the unofficial consensus can run ahead of the published estimate, and guidance often matters more than the backward-looking beat. The next report is scheduled for October 27, 2026, before the market opens, with current consensus EPS at $0.09574.

For readers who want a deeper dive into how institutional analysts currently view Centene, what their consensus targets imply, and how the stock stacks up against peers, the full institutional verdict page offers the complete analyst picture.